GTCR/Surmodics: Private Equity Firm’s Economist Disputes FTC’s Contention That Merged Company Would Dominate Hydrophilic Coatings Market

Published on Sep 02, 2025

The FTC’s estimate that GTCR’s acquisition of Surmodics (SRDX) would create a company that produces 60% of the hydrophilic coatings for medical devices in the U.S. is far too high, the private equity firm’s economics expert said in court today. Instead, the market share would be 27%, said Paul Wong, a director of economic consulting […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2025 The Capitol Forum. All Rights Reserved.